Table 1 Characteristics of the included studies
From: Dosimetry study of three-dimensional print template for 125I implantation therapy
Ref | First author and year | Number of patients | Template | Tumor size | Prescription dose (Gy) | Tumor site | Outcomes | |||
|---|---|---|---|---|---|---|---|---|---|---|
Template | Free hand | Template | Free hand | Dosimetric parameter | Operation time | |||||
1 | Hongtao [12] 2016 | 13/14 | 3DPNCT | NA | NA | 85.00 ± 33.10 | 84.43 ± 28.89 | Multiple lesions | √ |  |
2 | Han [13] 2017 | 15/25 | 3DPNCT | ≤ 3 cm: 14(lessions), 3–8 cm: 29, > 8 cm: 4 | ≤ 3 cm: 27, 3–8 cm:34, > 8 cm: 5 | 120 | 120 | Liver | √ | √ |
3 | Huang [14] 2018 | 12/13 | 3DPCT | ≤ 3 cm: 1, 3–5 cm:10, > 5 cm: 1 | ≤ 3 cm: 3, 3–5 cm:9, > 5 cm: 1 | 140 | 140 | Pancreas | √ |  |
4 | Cao [15] 2017 | 10/10 | 3DPCT | NA | NA | 120–160 | 120–160 | Lung | √ |  |
5 | Pan [16] 2018 | 30/30 | 3DPNCT | 64.4 ± 58.4(cc) | 67.8 ± 60.4(cc) | 119.46 ± 11.57 | 118.31 ± 11.41 | Multiple lesions | √ | √ |
6 | Shen [17] 2018 | 28/32 | 3DPNCT | ≤ 3 cm: 11, > 3 cm: 17 | ≤ 3 cm: 9, > 3 cm: 23 | 125.60 ± 23.60 | 123 ± 17.80 | Head and neck | √ | √ |
7 | Zheng [18] 2019 | 13/10 | 3DPCT | 25.9 ± 9.4 | 20.1 ± 5.3 | 90–120 | Mediastinal lymph nodes | √ |  | |
8 | Di [19] 2017 | 7/18 | 3DPNCT |  ≤ 5 cm: 13,  > 5 cm: 12 | 60–100 | Para-aortic lymph node | √ |  | ||
9 | Ji [20] 2017 | 21 | 3DPNCT | 61.10 (4.0–263.0) cm 3 | NA | Paravertebral/retroperitoneal Malignant Tumors | √ |  | ||
10 | Wang [21] 2016 | 10 | 3DPNCT | NA | NA | Pelvic recurrent rectal cancer | √ |  | ||
11 | Yuliang [22] 2016 | 15 | 3DPNCT | 71.0 (7.0–167.3) cm 3 | 110–150 Gy | Pelvic recurrent cancer | √ |  | ||
12 | Jiang [23] 2017 | 9 | 3DPNCT | 68.63 ± 62.83 cm 3 | 120 (110–160)Gy | Pelvic recurrent cervical cancer | √ |  | ||
13 | Zhe [24] 2017 | 21 | 3DPNCT | 77.1(6.5–411.6)cm 3 | 150 (110–180)Gy | Chest malignant tumor | √ |  | ||
14 | Ji [25] 2019 | 33 | Both | 36.2(3.2–204.5)cm 3 | 160 (120–170)Gy | Peripheral lung cancer | √ |  | ||
15 | Ang [26] 2019 | 37 | Both | 40.0(4.6–332.4)cm 3 | 140 (100–180)Gy | Pelvic wall recurrent gynecological Malignant tumors | √ |  | ||
16 | Xuemin [27] 2018 | 10 | Both | NA | NA | Superficial sarcoma | √ |  | ||